These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients. Shah MH; Bokhari MZ; Bokhari MT; Farooq A; Yousaf SM Transplant Proc; 2003 Nov; 35(7):2737-8. PubMed ID: 14612099 [No Abstract] [Full Text] [Related]
16. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Offner G; Broyer M; Niaudet P; Loirat C; Mentser M; Lemire J; Crocker JF; Cochat P; Clark G; Chodoff L; Korn A; Hall M Transplantation; 2002 Oct; 74(7):961-6. PubMed ID: 12394837 [TBL] [Abstract][Full Text] [Related]
17. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Vincenti F; Monaco A; Grinyo J; Kinkhabwala M; Neylan J; Roza A; Somberg K Transplant Proc; 2001; 33(1-2):1011-2. PubMed ID: 11267168 [No Abstract] [Full Text] [Related]
18. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. Keown P; Balshaw R; Khorasheh S; Chong M; Marra C; Kalo Z; Korn A BioDrugs; 2003; 17(4):271-9. PubMed ID: 12899644 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation. Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374 [No Abstract] [Full Text] [Related]